ProCE Banner Activity

EPCORE NHL-5: Results From Arm 1 of a Phase Ib/II Trial Evaluating SC Epcoritamab + Lenalidomide in Relapsed/Refractory DLBCL

Conference Coverage

In the EPCORE NHL-5 study, the combination of epcoritamab with lenalidomide demonstrated deep and durable responses in patients with R/R DLBCL.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.